Immutep (IMMP) Competitors $2.03 -0.09 (-4.25%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMP vs. SPRY, CALT, ANIP, SNDX, RCKT, BCYC, AVDL, COLL, SEPN, and BCAXShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include ARS Pharmaceuticals (SPRY), Calliditas Therapeutics AB (publ) (CALT), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), Avadel Pharmaceuticals (AVDL), Collegium Pharmaceutical (COLL), Septerna (SEPN), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Immutep vs. ARS Pharmaceuticals Calliditas Therapeutics AB (publ) ANI Pharmaceuticals Syndax Pharmaceuticals Rocket Pharmaceuticals Bicycle Therapeutics Avadel Pharmaceuticals Collegium Pharmaceutical Septerna Bicara Therapeutics ARS Pharmaceuticals (NASDAQ:SPRY) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do institutionals & insiders hold more shares of SPRY or IMMP? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 40.1% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Immutep shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor SPRY or IMMP? Immutep received 293 more outperform votes than ARS Pharmaceuticals when rated by MarketBeat users. However, 82.61% of users gave ARS Pharmaceuticals an outperform vote while only 72.56% of users gave Immutep an outperform vote. CompanyUnderperformOutperformARS PharmaceuticalsOutperform Votes1982.61% Underperform Votes417.39%ImmutepOutperform Votes31272.56% Underperform Votes11827.44% Which has better earnings & valuation, SPRY or IMMP? Immutep has higher revenue and earnings than ARS Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$2.57M423.10-$54.37M-$0.51-21.92Immutep$5.14M57.45-$28.01MN/AN/A Which has more volatility & risk, SPRY or IMMP? ARS Pharmaceuticals has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Is SPRY or IMMP more profitable? Immutep's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ARS PharmaceuticalsN/A -22.56% -21.82% Immutep N/A N/A N/A Does the media refer more to SPRY or IMMP? In the previous week, ARS Pharmaceuticals had 1 more articles in the media than Immutep. MarketBeat recorded 6 mentions for ARS Pharmaceuticals and 5 mentions for Immutep. ARS Pharmaceuticals' average media sentiment score of 0.50 beat Immutep's score of 0.23 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immutep 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate SPRY or IMMP? ARS Pharmaceuticals presently has a consensus target price of $24.00, suggesting a potential upside of 114.67%. Immutep has a consensus target price of $8.50, suggesting a potential upside of 318.72%. Given Immutep's higher probable upside, analysts clearly believe Immutep is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryARS Pharmaceuticals beats Immutep on 9 of the 16 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$295.28M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales57.45195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book1.935.104.794.78Net Income-$28.01M$151.51M$120.07M$225.60M7 Day Performance-6.88%-2.15%-1.89%-1.24%1 Month Performance10.33%-3.14%11.45%3.36%1 Year Performance-11.35%11.50%30.61%16.58% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep1.4184 of 5 stars$2.03-4.2%$8.50+318.7%-13.2%$295.28M$5.14M0.002,021SPRYARS Pharmaceuticals3.1441 of 5 stars$12.27+3.1%$24.00+95.6%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageCALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180ANIPANI Pharmaceuticals4.836 of 5 stars$56.07-0.9%$77.71+38.6%+1.9%$1.18B$555.46M-102.89642Insider TradeSNDXSyndax Pharmaceuticals3.9607 of 5 stars$13.73-1.4%$37.64+174.1%-33.6%$1.17B$16M-3.84110News CoverageRCKTRocket Pharmaceuticals4.8494 of 5 stars$11.99-0.2%$51.00+325.4%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.6084 of 5 stars$15.46+11.9%$36.00+132.9%-18.8%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeAVDLAvadel Pharmaceuticals2.6635 of 5 stars$10.93+5.2%$24.43+123.5%-24.0%$1.05B$138.16M-13.15154Positive NewsCOLLCollegium Pharmaceutical3.8414 of 5 stars$30.65+1.9%$42.60+39.0%-0.4%$988.46M$599.25M12.97210News CoveragePositive NewsSEPNSepterna2.2189 of 5 stars$21.81-2.6%$43.67+100.2%N/A$968.36MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.75+1.4%$43.00+142.3%N/A$965.88MN/A0.0032News CoverageGap Down Related Companies and Tools Related Companies ARS Pharmaceuticals Alternatives Calliditas Therapeutics AB (publ) Alternatives ANI Pharmaceuticals Alternatives Syndax Pharmaceuticals Alternatives Rocket Pharmaceuticals Alternatives Bicycle Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Collegium Pharmaceutical Alternatives Septerna Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMP) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
